Related references
Note: Only part of the references are listed.Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
Xiaoxiao Wang et al.
JOURNAL OF CLINICAL MEDICINE (2023)
Novel classes of immunotherapy for breast cancer
Alberto Hernando-Calvo et al.
BREAST CANCER RESEARCH AND TREATMENT (2022)
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
Leisha A. Emens et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Immune Classification and Immune Landscape Analysis of Triple-Negative Breast Cancer
Shaojun Hu et al.
FRONTIERS IN GENETICS (2021)
Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies
Elizabeth Sakach et al.
CLINICAL BREAST CANCER (2021)
How an amino acid affects a key cell-growth regulator
Tibor Vellai
NATURE (2021)
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma
Kohei Shigeta et al.
HEPATOLOGY (2020)
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Preeti Narayan et al.
CLINICAL CANCER RESEARCH (2020)
CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils
Xichen Zheng et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Chronic mTOR activation induces a degradative smooth muscle cell phenotype
Guangxin Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer
K. G. K. Deepak et al.
PHARMACOLOGICAL RESEARCH (2020)
Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Antitumor Efficacy of PD-1 Blockade
Eric T. Alexander et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack et al.
FRONTIERS IN IMMUNOLOGY (2020)
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
John D. Martin et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 81 (2019)
Targeting the PI3-kinase pathway in triple-negative breast cancer
J. Pascual et al.
ANNALS OF ONCOLOGY (2019)
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
Jichao He et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress
Afsane Bahrami et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Ricardo L. B. Costa et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer
In Hae Park et al.
JOURNAL OF CANCER (2018)
The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
Chloe Grasselly et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD4+ T Cell Activation and Vascular Normalization: Two Sides of the Same Coin?
Michele De Palma et al.
IMMUNITY (2017)
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Lin Tian et al.
NATURE (2017)
Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma
Lei Qin et al.
NEURORADIOLOGY (2017)
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab
Reva K. Basho et al.
JAMA ONCOLOGY (2017)
Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery
Soo Jung Kim et al.
CANCER LETTERS (2017)
mTOR (Mechanistic Target of Rapamycin) Inhibition Decreases Mechanosignaling, Collagen Accumulation, and Stiffening of the Thoracic Aorta in Elastin-Deficient Mice
Yang Jiao et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Inhibition of the mTOR pathway in abdominal aortic aneurysm: implications of smooth muscle cell contractile phenotype, inflammation, and aneurysm expansion
Guangxin Li et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2017)
Pharmacologically Improved Contractility Protects Against Aortic Dissection in Mice With Disrupted Transforming Growth Factor-β Signaling Despite Compromised Extracellular Matrix Properties
Jacopo Ferruzzi et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer
Domenico Ribatti et al.
TRANSLATIONAL ONCOLOGY (2016)
The Role of the Tumor vasculature in the Host immune Response: implications for Therapeutic Strategies Targeting the Tumor Microenvironment
Shona A. Hendry et al.
FRONTIERS IN IMMUNOLOGY (2016)
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
Jasmeet Chadha Singh et al.
BREAST CANCER RESEARCH (2014)
Strategies for the management of adverse events associated with mTOR inhibitors
Bruce Kaplan et al.
TRANSPLANTATION REVIEWS (2014)
Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells
Chen Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells
Mayu Yunokawa et al.
CANCER SCIENCE (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Time-Course Imaging of Therapeutic Functional Tumor Vascular Normalization by Antiangiogenic Agents
Qingbei Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Peter Carmeliet et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
PI3K/AKT/mTOR pathway in angiogenesis
Jayashree Karar et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2011)
mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Heidi A. Lane et al.
CLINICAL CANCER RESEARCH (2009)
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
Susan L. Ellard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature:: Implications for clinical imaging
Christian R. Schnell et al.
CANCER RESEARCH (2008)
Basal-like breast cancer: A critical review
Emad A. Rakha et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Share Paper
